Sectoral Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Sectoral Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,540	Closed	-$124K	–	84
2025 Q2	$124K	Hold	2,540	–	–	0.08%	92
2025 Q1	$86.4K	Buy	+2,540	New	+$108K	0.07%	82
2023 Q1	–	Sell	-2,490	Closed	-$101K	–	121
2022 Q4	$101K	Hold	2,490	–	–	0.02%	120
2022 Q3	$163K	Hold	2,490	–	–	0.03%	106
2022 Q2	$151K	Sell	2,490 -780	-24%	-$45.9K	0.03%	108
2022 Q1	$205K	Hold	3,270	–	–	0.04%	106
2021 Q4	$248K	Hold	3,270	–	–	0.04%	105
2021 Q3	$366K	Hold	3,270	–	–	0.03%	122
2021 Q2	$529K	Hold	3,270	–	–	0.04%	114
2021 Q1	$398K	Sell	3,270 -21,700	-87%	-$3.28M	0.03%	106
2020 Q4	$3.82M	Buy	+24,970	New	+$2.95M	0.27%	73
2020 Q3	–	Sell	-114,400	Closed	-$8.41M	–	112
2020 Q2	$8.41M	Buy	114,400 +103,650	+964%	+$6.06M	0.77%	51
2020 Q1	$456K	Buy	+10,750	New	+$555K	0.09%	64

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sectoral Asset Management's CRSP Position: Q3 2025 in Review

Sectoral Asset Management sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 2,540 shares — an estimated $124K sold.

Sectoral Asset Management first reported a position in CRSP in Q1 2020 and held it in 13 quarters. The position peaked at $8.41M in Q2 2020. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Sectoral Asset Management reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Sectoral Asset Management sold 2,540 CRISPR Therapeutics shares in Q3 2025, an estimated $124K.
Sectoral Asset Management first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 13 quarters.
Sectoral Asset Management's CRISPR Therapeutics position peaked at $8.41M in Q2 2020.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Sectoral Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.